Argos Therapeutics Inc. (NASDAQ:ARGS) major shareholder International S. Pharmstandard bought 31,704 shares of the company’s stock in a transaction that occurred on Friday, October 7th. The shares were bought at an average price of $4.73 per share, with a total value of $149,959.92. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) opened at 4.61 on Monday. Argos Therapeutics Inc. has a 52 week low of $1.61 and a 52 week high of $13.97. The stock’s market cap is $189.91 million. The stock has a 50 day moving average of $4.89 and a 200 day moving average of $5.89.

Argos Therapeutics (NASDAQ:ARGS) last posted its earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.05. On average, analysts expect that Argos Therapeutics Inc. will post ($1.56) earnings per share for the current year.

Insider Buying and Selling by Quarter for Argos Therapeutics (NASDAQ:ARGS)

ARGS has been the subject of a number of research reports. Zacks Investment Research upgraded shares of Argos Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Monday, August 15th. FBR & Co lowered their price objective on shares of Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 11th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $11.00 price objective on shares of Argos Therapeutics in a research report on Monday, June 20th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $11.50.

Several institutional investors have recently bought and sold shares of ARGS. California State Teachers Retirement System purchased a new position in Argos Therapeutics during the second quarter valued at $137,000. Schwab Charles Investment Management Inc. purchased a new position in Argos Therapeutics during the second quarter valued at $137,000. KCG Holdings Inc. purchased a new position in Argos Therapeutics during the second quarter valued at $163,000. BlackRock Investment Management LLC raised its position in Argos Therapeutics by 2,162.3% in the second quarter. BlackRock Investment Management LLC now owns 39,567 shares of the biopharmaceutical company’s stock valued at $243,000 after buying an additional 37,818 shares during the period. Finally, Geode Capital Management LLC raised its position in Argos Therapeutics by 7.9% in the first quarter. Geode Capital Management LLC now owns 48,851 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 3,559 shares during the period. 11.03% of the stock is owned by hedge funds and other institutional investors.

Argos Therapeutics Company Profile

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

5 Day Chart for NASDAQ:ARGS

Receive News & Stock Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related stocks with our FREE daily email newsletter.